| 2019-04-08 |
Predominant global glomerulosclerosis in patients of upper urinary tract urothelial carcinoma with pre-existing renal function impairment is a predictor of poor renal outcomes |
BMC Cancer. 2019 Apr 8;19:Article number 337. |
 |
| 2019-03 |
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens |
Gastric Cancer. 2019 Mar;22(2):344-354. |
|
| 2019-03 |
Foreword |
Hepatobiliary Surgery and Nutrition. 2019 Mar;8(Suppl. 1):S1. |
|
| 2019-02 |
ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-beta-catenin signaling |
Oncogene. 2019 Feb;38(8):1340-1353. |
|
| 2019-02 |
ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-beta-catenin signaling [Erratum: Oncogene. 2019 Feb;38(8):1340-1353.] |
Oncogene. 2019 Feb;38(8):1354. |
|
| 2019-02 |
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (attraction-4) |
Annals of Oncology. 2019 Feb;30(2):250-258. |
|
| 2019-02 |
NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors |
European Journal of Cancer. 2019 Feb;108:78-87. |
|
| 2019-02 |
Mutational landscape by targeted next-generation sequencing in EBV-associated lymphoepithelioma-like cholangiocarcinoma |
Journal of Clinical Oncology. 2019 Feb;37(4, Suppl.):Abstract number 269. |
|
| 2019-02 |
A multicenter, phase Ib/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment of naive, advanced, or metastatic biliary tract cancer (BTC) |
Journal of Clinical Oncology. 2019 Feb;37(4, Suppl.):Abstract number 319. |
|
| 2019-02 |
Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2 |
Journal of Clinical Oncology. 2019 Feb;37(4, Suppl.):Abstract number 8. |
|
| 2019-02 |
A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements |
Journal of Clinical Oncology. 2019 Feb;37(4, Suppl.):Abstract number TPS468. |
|
| 2019-01 |
Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin |
European Journal of Cancer. 2019 Jan;106:24-33. |
|
| 2019-01 |
Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic gastric cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS |
Annals of Oncology. 2019 Jan;30(1):19-33. |
|
| 2019-01 |
Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic oesophageal cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS |
Annals of Oncology. 2019 Jan;30(1):34-43. |
|
| 2019-01 |
Beta-catenin-activated autocrine PDGF/Src signaling is a therapeutic target in pancreatic cancer |
Theranostics. 2019 Jan;9(2):324-336. |
|
| 2018-12-20 |
Protein arginine methyltransferase 3 enhances chemoresistance in pancreatic cancer by methylating hnRNPA1 to increase ABCG2 expression |
Cancers. 2018 Dec 20;11(1):Article number 8. |
|
| 2018-12 |
c-Myc promotes lymphatic metastasis of pancreatic neuroendocrine tumor through VEGFC upregulation |
Cancer Science. 2018 Dec;109(Suppl. 2):866. |
|
| 2018-12 |
The epidemiology of gastric cancer in the era of H. pylori eradication: A nation-wide registry-based study in Taiwan |
Cancer Science. 2018 Dec;109(Suppl. 2):1437. |
|
| 2018-12 |
FOXO3a-driven alternation of metabolism dictates the gemcitabine sensitivity |
Cancer Science. 2018 Dec;109(Suppl. 2):871. |
|
| 2018-11-13 |
From friend to enemy: Dissecting the functional alteration of immunoregulatory components during pancreatic tumorigenesis |
International Journal of Molecular Sciences. 2018 Nov 13;19(11):Article number 3584. |
|
| 2018-11-07 |
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial |
European Journal of Cancer. 2018 Nov 7;105:71-78. |
|
| 2018-11 |
The incidence and survival of pancreatic cancer by histology, including rare subtypes: A nation-wide cancer registry-based study from Taiwan |
Cancer Medicine. 2018 Nov;7(11):5775-5788. |
|
| 2018-11 |
TCOG T1308 study: The final results of a phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer |
Annals of Oncology. 2018 Nov;29(Suppl. 9):50. |
|
| 2018-11 |
Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 study |
Annals of Oncology. 2018 Nov;29(Suppl. 9):Meeting Abstract 200P. |
|
| 2018-11 |
M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor beta (TGF-beta) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype |
Annals of Oncology. 2018 Nov;29(Suppl. 9):Meeting Abstract 153O. |
|
| 2018-10 |
Multicenter, phase II trial of biweekly S-1, leucovorin (LV), oxaliplatin and gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma (mPDAC): Final report of TCOG T1211 study |
Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 736P. |
|
| 2018-10 |
NAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) |
Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 733P. |
|
| 2018-10 |
The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) |
Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 749P. |
|
| 2018-10 |
Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1 |
Annals of Oncology. 2018 Oct;29(Suppl. 8):250-251. |
|
| 2018-10 |
M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-beta, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial |
Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 757P. |
|
| 2018-10 |
Randomized, phase III trial comparing adjuvant gemcitabine (Gem) versus Gem plus chemoradiation (CCRT) in curatively resected pancreatic ductal adenocarcinoma (PDAC): A Taiwan cooperative oncology group study |
Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 626PD. |
|
| 2018-09 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials |
Oncology Research and Treatment. 2018 Sep;41(Suppl. 4):285-286. |
|
| 2018-08-24 |
BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor |
Cancer Science. 2018 Nov;109(11):3591-3601. |
|
| 2018-07 |
The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients |
Journal of the Chinese Medical Association. 2018 Jul;81(7):593-598. |
|
| 2018-06 |
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma |
Annals of Oncology. 2018 Jun;29(6):1402-1408. |
|
| 2018-06 |
The effect of best response to prior anticancer therapy on efficacy outcomes in the napoli-1 trial of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy |
Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-152. |
|
| 2018-06 |
Decreased appetite (DA) at baseline impacts prognosis in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC) |
Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-153. |
|
| 2018-06 |
Prognostic effect of primary tumor location in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC) |
Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-150. |
|
| 2018-06 |
Selected subgroup analyses of liposomal irinotecan (nal-IRI) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the global NAPOLI-1 phase III trial |
Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract O-004. |
|
| 2018-06 |
Prognostic value of baseline biliary stents on outcomes in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the NAPOLI-1 trial |
Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-151. |
|
| 2018-05 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials |
Journal of Clinical Oncology. 2018 May;36(15, Suppl.):Abstract number e15127. |
|
| 2018-05 |
A phase Ib study of ADI-PEG 20 plus pembrolizumab in advanced solid cancers |
Journal of Clinical Oncology. 2018 May;36(15, Suppl. S):Meeting Abstract 2556. |
|
| 2018-05 |
A survival prediction nomogram for liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy |
Journal of Clinical Oncology. 2018 May;36(15, Suppl.):Meeting Abstract e16204. |
|
| 2018-04 |
The role of consolidation chemoradiotherapy in Locally Advanced Pancreatic Cancer receiving chemotherapy: An updated systematic review and meta-analysis |
Cancer Research and Treatment. 2018 Apr;50(2):562-574. |
|
| 2018-04 |
Dialysis increases the risk of bladder recurrence in patients with Upper Tract Urothelial Cancer: A population-based study |
Annals of Surgical Oncology. 2018 Apr;25(4):1086-1093. |
|
| 2018-03 |
Beau's lines in nails: An indicator of recent Docetaxel and 5-FU use |
Kaohsiung Journal of Medical Sciences. 2018 Mar;34(3):181-183. |
|
| 2018-03 |
Cure of unresectable, locally advanced pancreatic cancer after multidisciplinary therapy |
Journal of Cancer Research and Practice. 2018 Mar;5(1):27-31. |
|
| 2018-02-01 |
Myeloid-derived macrophages and secreted HSP90alpha induce pancreatic ductal adenocarcinoma development |
OncoImmunology. 2018 Feb 1;7(5):Article number e1424612. |
|
| 2018-02 |
Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI-1: A phase III study of liposomal irinotecan (nal-IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pan |
Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 460. |
|
| 2018-02 |
Nomogram for predicting overall survival (OS) in patients (pts) treated with liposomal irinotecan (nal-IRI) +/- 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy in NAPOLI-1. |
Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 459. |
|
